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Cell membraneWnt3a binds Frizzled-1 and the LRP5/6 co-receptors, ultimately activating Lef/Tcf-sensitive gene transcription in
development. Inositol polyphosphate multikinase, IPMK, which possesses inositol phosphate kinase and lipid
inositol kinase activities, is essential in Wnt3a regulation of its canonical pathway as well as physiologically in
AMPK signaling. In the current report we show that translocation of IPMK to the cell membrane, where its sub-
strates exist in high abundance, is obligate to its function in Wnt signaling. Translocation of IPMK to the cell
membrane occurs within 5 min after Wnt3a stimulation. IPMK ducking onto Dishevelled-3 (Dvl3) requires a
PDZ domain and the COOH-terminal prolyly-rich tail of Dvl3. Wnt3a-stimulates mobilization of Dvl3 to the
cellmembrane, translocating IPMK to the cellmembrane also, to facilitate downstreamsignaling of Frizzled1.De-
letion mutant of IPMK lacking the NH2-terminal variable region, IPMKΔN, fails to translocate to the cell mem-
brane and to propagate canonical signaling. Targeting the IPMKΔN back to the cell membrane by addition of
an isoprenylated CAAX box rescues its function in Wnt3a downstream signaling.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Wnt activation of Lef/Tcf-sensitive transcription is the hallmark of
the canonical pathway in development [1–3]. In mouse embryonal
teratocarcinoma totipotent cells (F9), expression of rat Frizzled-1 con-
fers Wnt3a sensitivity, activation of Lef/Tcf-sensitive transcription
[4,5], and formation of parietal endoderm [4]. Inositol 1,4,5-trisphos-
phate 3-kinase (IP3 3-kinase) and inositol polyphosphate multikinase
(IPMK) are essential to production of inositol pentakisphosphate (IP5)
[6–9] and to canonical signaling by Wnt3a [10]. Previously we showed
that Wnt3a stimulation of the canonical pathway generates IP5, which
acts to inhibit the activity of glycogen synthase kinase-3β, and to acti-
vate casein kinase 2. The consequence is accumulation of cytosolic
β-catenin and subsequent activation of lymphoid enhancer factor/
T-cell factor protein (Lef/Tcf)-dependent transcription [10]. Equally
essential is the role of Dishevelled (Dvl), in particular Dvl3, in organizing
large supermolecular complexes (i.e., signalsomes) necessary for signal-
ing downstream from Frizzled-1 [11,12]. Dvl supermolecular complexes
operate as mobile scaffolds, intracellular “toolboxes” that organize
signaling partners temporally and spatially. To further understand the
role of Dvl3 in IPMK signaling we interrogated the interaction between
the Dvl3-based scaffold and this lipid kinase. Wnt3a is shown to stimu-
late docking of IPMK to the scaffold. Docking of IPMK to Dvl3 requires
both the PDZ domain and COOH-terminal prolyl-rich tail of Dvl3. The
elimination of either the DIX or the DEP domains does not affect docking+1 631 444 7696.
ang).
-NC-ND license.of IPMK. The translocation of IPMK to the cell membrane rich in its sub-
strate molecules requires both Dvl3 as well as Wnt3a activation.
2. Material and methods
2.1. Reagents
Recombinant mouse Wnt3a (Cat#1324-WN) was purchased from
R&D System (Minneapolis, MN). Anti-Myc (M4439) and anti-β-catenin
(C2206) antibodies were purchased from Sigma. Anti-Dvl3 (4D3,
sc-8027) was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Alexa Fluor® 488 labeled secondary antibodies were obtained from
Life Technologies (Grand Island, NY). The antibody against mouse IPMK
was a kind gift from Dr. Sangwon F. Kim (University of Pennsylvania,
School of Medicine, Philadelphia, PA). Small interfering RNAs were pur-
chased both from Ambion (Corvallis, OR) and Life Technologies (Grand
Island, NY).
2.2. Constructs
Rat IPMK sequence was ampliﬁed by PCR, digested by restriction
enzymes EcoRI and BglII and inserted into peGFP-C1 vector (Clontech).
A similar strategy was used to generate pcDNA3-based constructs of
human IPMK with either Myc-tag or HA-tag at N-terminus of IPMK.
For construction of hIPMKΔN (deletion of 1–77 amino acids from the
N-terminus of human IPMK) the following primers were designed and
employed to amplify the insert: 5′‐GAAGATCTCTCAACCACCTCCAA
GGGGC-3′ (forward primer); 5′-GGGGTACCTCAATTGTCTAAAATACTTC
GAAGTACA-3′ (reverse primer). For construction of hIPMKΔN‐CAAX
(hIPMKΔN with a CAAX box at its C-terminus), the following primer
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AGGGGC-3′ (forward primer); 5′‐GGGGTACCTTACATAATTACACACTTT
GTCTTTGACTTCTTTTTCTTCTTTTTACCATCATTGTCTAAAATACTTCGAAGT
ACA-3′ (reverse primer). Human Dvl3 cDNA fragments were generated
by PCR ampliﬁcation by using the following primers:
DIX domain, forward 5′-GGAATTCGGATGGGCGAGACCAAGATC
ATC-3′, reverse 5′-CCGCTCGAGTCACTCAGCTGACACCAGCCA-3′;
Linker 1 domain, forward 5′-GGAATTCGGGCCTCACACCCAGACCC
A-3′, reverse 5′-CCGCTCGAGTCAGTTGAGTGACATGGTGGAGT-3′;
PDZ domain, forward 5′-GGAATTCGGATCATCACGGTCACTCTCAA-
3′, reverse 5′‐CCGCTCGAGTCAGGCAACAGTCAGGGTGATGG-3′;
Linker 2 domain, forward 5′-GGAATTCGGGCCAAGTGCTGGGACCC
A-3′, reverse 5′-CCGCTCGAGTCACATGTCACTGTGGATGGACAA-3′;
DEP domain, forward 5′-GGAATTCGGGCTGCCATCGTAAAAGCCA
TG-3′, reverse 5′-CCGCTCGAGTCAGTCACCGAAGATGTAGTAGC-3′;
Cter domain, forward 5′-GGAATTCGGCTCTGCGGCAACATGGCCAA
C-3′, reverse 5′-CCGCTCGAGTCACATCACATCCACAAAGAA-3′.
PCR products were digested with EcoRI and XhoI and inserted into
pGEX-4T-2 vector. All constructs were veriﬁed by DNA sequencing.
2.3. Cell culture and transfection
Mouse teratocarcinoma F9 cells were propagated in Dulbecco's
modiﬁed Eagle's medium (Cellgro, Manassas, VA) supplemented
with fetal bovine serum (15%, Hyclone, South Logan, UT), penicillin
(100 units/ml) and streptomycin (0.1 mg/ml) in a humidiﬁed atmo-
sphere of 5% CO2 at 37 °C. All clones, simply termed the “clones” here-
in, were stably co-transfected with pcDNA3.1 harboring rat Frizzled-1
(Rfz1) and Lef/Tcf-luciferase reporter (Super8xTOPFlash, a kind gift
from Dr. Randall Moon, University of Washington, Seattle, WA) were se-
lected in complete medium containing neomycin analogue, G418
(0.4 mg/ml). At least three independent clones which contained both
Rfz1 and Super8xTOPFlash were propagated. Lipofectamine 2000 and
Lipofectamine RNAiMax (Life Technologies) were used to introduce plas-
mid DNA and siRNA, respectively, into cultured cells according to the
manufacturer's instructions.
2.4. Immunoprecipitation and immunoblotting
Cells were harvested and lysed in lysis buffer containing 137 mM
NaCl, 20 mM Tris (pH 7.5), 100 mM NaCl, 10 mM sodium molybdate,
1 mM Na3VO4, 10% glycerol, 1% NP-40 and a cocktail of protease inhibi-
tors from Roche. Pellets were spun down by centrifugation at 14,000×g
for 10 min at 4 °C. The supernatant (total cell lysates) was collected and
protein concentration was measured as described. For pull-downs, 1 or
2 mg (protein) of total cell lysates were incubated with either
anti-c-Myc agarose beads (#A7470, Sigma) or anti-Dvl3 antibody
(Santa Cruz biotechnology) chemically linked to protein A/G agarose. Im-
mune complexes were collected by centrifugation and washed with cold
RIPA buffer (20 mM Tris, pH 8.0; 150 mMNaCl, 5 mM EDTA and 1% Tri-
ton X-100) for 3 times. Proteins collected by immune complexeswere re-
solved from antibody-protein A/G agarose by boiling the sample in 20 μl
of Laemmli solution for 5 min. Samples from immunoprecipitation or
total cell lysates (50–100 μg protein/lane) were subjected to SDS-PAGE
for separation. The resolved proteins were transferred onto nitrocellulose
membranes. Blots were rinsed with buffer, incubated with primary and
then secondary antibodies. Immune complexes were made visible by
using an enhanced chemiluminescence method.
2.5. Knock-down protocol by using small interfering RNA
Duplexed siRNA with following sequences: UCUCCAGUGGUUU
GAAAAUCAGAAG and CUUCUGAUUUUCAAACCACUGGAGA; GGAAGAGAUCUCGGACGACtt and GUCGUCCGAGAUCUCUUCCtt were used
to target mouse IPMK and Dvl3 in F9 cells, respectively. To knock-
down endogenous IPMK or Dvl3, reverse transfection was performed
by using Lipofectamine RNAiMax, according to the manufacturer's
protocol. Brieﬂy, siRNA duplexes were mixed with Lipofectamine
RNAiMax. The mixture was added into cell culture plates at a ﬁnal
concentration of 20 nM for siRNA duplexes. Suspensions of F9 cells
were then seeded onto culture wells and cultured for 48 h. For rescue
experiments, constructs of hIPMK were introduced into cells by using
Lipofectamine 2000 at 24 h following addition of the siRNA targeting
IPMK.
2.6. Lef/Tcf-sensitive transcription assay
F9 clones stably transfected with Rfz1 and Super8xTOPFlash were
cultured in 12 well plates and stimulated with Wnt3a (20 ng/ml) for
5 h. Cell lysates were collected in reporter lysis buffer (Cat# E397A,
Promega, Madison, WI). Cell lysates (10 μl) were incubated for 10 s
with 100 μl of a reaction mixture containing 0.67 mM luciferin,
0.27 mM Coenzyme A, 0.1 mM EDTA, 1.1 mM MgCO3, 4 mM MgSO4
and 20 mM Tricine, pH 7.8. The intensity of luminescence was mea-
sured immediately using a luminometer (Lumat LB 9507, Berthold Tech-
nologies, Oak Ridge, TN). Samples were assayed in triplicate and the
luciferase activity was normalized based on protein concentration.
2.7. Preparation of subcellular fractionation
Cells propagated in P150 Petri dishes were treated with or without
puriﬁed Wnt3a for the time periods indicated in the ﬁgure legends.
Cells were washed with phosphate-buffered saline twice, and then
suspended in ice-cold buffer A (10 mM Hepes, pH 7.0, 5 mM MgCl2,
25 mM KCl, 1 mM Na3VO4, 1 mM phenylmethylsulphonyl ﬂuoride,
10 μg/ml leupeptin, and 10 μg/ml aprotinin). Cells were disrupted
by repeated passage of cell suspension through a 23-gauge needle.
An equal volume of ice-cold buffer A containing 0.25 M sucrose was
added immediately after the disruption. Nuclei and unbroken cells
were removed by centrifugation at 500×g for 10 min. The superna-
tant was transferred to a fresh tube and EDTA was added to a ﬁnal
concentration of 10 mM. The mixture was subjected to centrifugation
at 16,000×g for 15 min. The resultant pellets were washed once with
buffer A containing of 0.25 M sucrose and then were resuspended in a
RIPA buffer. This subcellular fractionation yields a cell membrane-
enriched fraction, high in cell membrane markers. The supernatant
is employed as the source of cytosol.
2.8. Live cell imaging
For live cell imaging, F9 cells stably expressing Rfz1were transfected
with pcDNA3 harboring rat IPMK-eGFP and seeded onto collagen-
coated glass-bottom culture dishes (MatTeck Corporation, Ashland,
MA) for 24 h. Cells were stimulated with Wnt3a and images were im-
mediately recorded by using a Zeiss LSM 510 META NLO Two-Photon
Laser Scanning Confocal Microscope (Microscopy Imaging Center,
Stony Brook University).
2.9. Indirect immunoﬂuorescence
Cells grown on glass-bottom dishes were ﬁrst washed twice with
DPBS buffer containing 0.9 mM CaCl2, 0.5 mM MgCl2, 2.7 mM KCl,
140 mM NaCl, 1.5 mM KH2PO4 and 8 mM NaH2PO4 and then ﬁxed
with 3.8% formaldehyde for 15 min at room temperature. Fixed cells
were permeabilized and incubated in DPBS buffer containing 2% bo-
vine serum albumin for 20 min. Cells then were incubated with
anti-c-Myc antibody (1:1000) at 37 °C for 30 min, washed with
DPBS buffer for 3 times and then incubated with Alexa Fluor® 488 la-
beled secondary antibody at 37 °C for 30 min. Fluorescence staining
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FV1000 confocal microscope.
2.10. Statistical analysis
All experiments were conducted minimally in triplicate sampling.
Data are expressed as the means±S.E. from at least three separate ex-
periments. Comparisons of data among groups were performed with
one-way analysis of variance followed by the Newman–Keuls test. Sta-
tistical signiﬁcance (p value of less than 0.01) is denoted with asterisks
or the pound symbols.
3. Results
3.1. IPMK regulates the Wnt canonical pathway
Functional analysis of the role of IPMKwasprobed inmouse F9 totipo-
tent cells expressing rat Frizzled-1, employing siRNA reagents that target
mouse IPMK (Fig. 1). Under these conditions, IPMK (44 kDa—Mr) was
suppressed ~80% by targeted siRNA. IPMK expression was unaffected by
treatment of the cells with commercially-prepared “control” siRNA
(Fig. 1A). Downstream activation of Lef/Tcf-sensitive transcriptional acti-
vation was analyzed using the Super8xTOPFlash reporter (Fig. 1B). At 5–
7 h post Wnt3a treatment, Lef/Tcf-sensitive transcription was activated.
Treating cells with siRNA targeting mouse IPMK sharply reduced Wnt3a
activation of the canonical pathway. Lipid-based signals provoked from
Wnt3a activation are derived, in part, by IPMK (aswell as IP3K). Transient
expression of Myc-tagged human IPMK (Myc-hIPMK) in the IPMK-
deﬁcient cells fully “rescues” the ability of Wnt3a to stimulate theFig. 1. IPMK regulates Wnt3a-stimulated canonical signaling. A, Knockdown of IPMK by siRNA in
oligos were employed as “control” for siRNA treatments (Ctrl). Immunoblots of actin displayed in
with vehicle (−), control siRNA (Ctrl) or siRNA targeting IPMK (mIPMK) for 24 h and therea
(Myc-hIPMK). Twenty four hours later, cells were treated with (+) or without (−)Wnt3a for 1 h
and graphed. B *pb0.001 versus control (−siRNA, +Wnt3a) group; C *pb0.01 versus control (−canonical pathway. Treating cells with commercially-prepared “control”
siRNA likewise did not alter the ability of Wnt3a to stimulate Lef/Tcf-
sensitive transcription. By measuring changes in cytosolic β-catenin
levels, Wnt3a signaling could be assessed at 1 h post-stimulation
(Fig. 1C). Wnt3a stimulates increased accumulation of cytosolic
β-catenin. Treating cells with siRNAs targeting mouse IPMK abolished
the β-catenin accumulation in response toWnt3a. Transient expression
of human IPMK in the siRNA-treated cells “rescues” the ability ofWnt3a
to elevate cytosolic β-catenin levels (Fig. 1C), conﬁrming its ability to
“rescue” Wnt3a-stimulated Lef/Tcf-sensitive transcriptional activation
at 5 h post-stimulation (Fig. 1B).
3.2. Wnt3a stimulates IPMK translocation to the cell membrane
IPMK is localized largely in the cytosol and nuclei (Fig. 2A). Inositol
trisphosphate (IP3) and inositol tetrakisphosphate (IP4), substrates for
IPMK, are generated at the inner leaﬂet of the cell membrane via hydro-
lysis of phosphatidyl inositol bisphosphate by phospholypase Cβ [13]
and subsequent phosphorylation of IP3 by IP3 3-kinase [14]. IPMK acts
of these substrates to generate IP5 in response to Wnt3a [10]. How
IPMK translocates to the cell membrane in response toWnt3a is a ques-
tion central to understanding the operation of the canonical pathway.
To answer this query, we investigated the effects of Wnt3a on IPMK
translocation. IPMK taggedwith eGFPwas expressed in F9 cells andﬂuo-
rescence microscopy performed to examine its localization (Fig. 2A).
Treating the cells with Wnt3a provoked a rapid translocation of IPMK to
the juxtamembrane and cell membrane regions. IPMK could be observed
in both regions even in the absence ofWnt. Treating the cells withWnt3a
provokedmore pronouncedmigration of IPMK to the cell membrane andF9 cells was analyzed by qPCR and immunoblotting. Commercial-designed and synthesized
panel A and C establish equivalent loading of protein samples. B and C, Clones were treated
fter cells were transfected with or without plasmids harboring Myc-tagged human IPMK
(C) or 6 h (B). Reporter activities (B) and cytosolic levels of beta-catenin (C) were analyzed
siRNA,−Wnt3a) group.
Fig. 2. Wnt3a stimulates IPMK translocation to the cell membrane. A, eGFP-tagged
IPMK was expressed transiently in F9 clones. Cells were cultured on a glass-bottom
culture dish and stimulated by Wnt3a. The ﬂuorescence images of eGFP-IPMK in live
cells were captured by using confocal microscopy as described in Materials and
methods. B, F9 clones were transiently transfected with either empty vector (−) or
pcDNA3 harboring Myc-IPMK for 24 h. Wnt3a was added into culture media and
thereafter cells were harvested at the indicated time periods. Cell membrane-
enriched subcellular fractions were isolated according to the protocol described. Dvl3
and Myc-IPMK content in cell membrane fractions were probed by immunoblotting.
Immunoblots of Na+/K+-ATPase mark cell membrane-enriched fractions and demon-
strate equal loading of samples. C, Clones were treated with vehicle (−), control siRNA
(Ctrl) or siRNA targeting Dvl3 for 24 h. Cells then were transfected with a plasmids
harboring Myc-IPMK for 24 h. Cell membrane-enriched subcellular fractions were col-
lected from cells treated with Wnt3a for 0, 5 and 30 min, respectively. Dvl3 and
Myc-IPMK in each sample were probed by immunoblotting and their relative abun-
dances in samples were compared by intensities of immunoblotting bands correspond-
ing to Dvl3 and Myc-IPMK. *pb0.01 versus control (−siRNA, +Wnt3a at 0 min) group.
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IPMK was obvious within 5 min of stimulation by Wnt3a. By 10–
15 min post-stimulation with Wnt3a, accumulation of IPMK at the plas-
ma membrane was prominent. These results observed by ﬂuorescencemicroscopy were tested biochemically, by examining the amounts of
Myc-tagged IPMK that can be found associated with the cell membrane.
A cell membrane-enriched (Na+/K+-ATPase-enriched) subcellular frac-
tion was probed for IPMK content (Fig. 2B, C). Both IPMK and Dvl3 asso-
ciation with the cell membrane was established in this subcellular
fraction using immunoblotting (Fig. 2B). A time-dependent accumula-
tion of Dvl3 in the cell membrane-enriched subcellular fraction in re-
sponse to Wnt3a was observed. In addition, Wnt3a stimulated a rapid,
transient increase in the amount of IPMK found in cell membrane-
enriched fraction (Fig. 2B, C).
The possibility that Dvl3, a mobile scaffold whichmigrates to the cell
membrane in response to Wnt3a, may be involved in IPMK targeting to
the cell membrane was tested. If Dvl3 translocates IPMK, loss of Dvl3
should block the translocation. To test this hypothesis, we made use of
siRNA to knock-down Dvl3 expression. We examined Myc-IPMK con-
tent in cell membrane-enriched fractions prepared from Dvl3-deﬁcient
F9 cells stimulated byWnt3a at 0, 5 and 30 min. Knockdown of Dvl3 ef-
fectively abolished Wnt3a-stimulated translocation of IPMK to the cell
membrane (Fig. 2C). In contrast, treating cells with control siRNA affect-
ed neither expression of Dvl3, nor translocation of IPMK to the cellmem-
brane in response to Wnt3a (Fig. 2C).
3.3. Wnt3a stimulates IPMK docking to Dvl3
We probed if the translocation of IPMK in response to Wnt3a in-
volved docking to Dvl3. Pull-downs of Dvl3 were prepared from lysates
of F9 cells transfected with Myc-tagged IPMK or vector alone (Fig. 3A).
Dvl3 is a phosphoprotein, herein displaying Mr=78 and 80 kDa,
reﬂecting the multiple phosphorylated nature of this scaffold protein
[12,15]. Wnt3a treatment stimulated increased content of Myc-tagged
IPMK in pull-downs of Dvl3 from lysates of F9 cells treated with
Wnt3a over a 30-min time course (Fig. 3B). The relative amount of
IPMK found in the Dvl3-based pull downs was maximal at 5 min post
Wnt3a stimulation, reaching about 6–7-fold over basal, untreated condi-
tions (Fig. 3C). This increase in Wnt3a stimulation in IPMK associated
with Dvl3 was transient, falling from the maximum at 5 min to less
than control levels by 30 min poststimulation. IPMK associates with
Dvl3, which is observed in Dvl3-based, very large supermolecular
signalsomes that have been observed and characterized by ﬂuorescence
microscopy (in vivo), large-bore steric exclusion chromatography (in
vitro) and ﬂuorescence correlation spectroscopy (in vivo, live cell,
real-time measurements) (Wang and Malbon, unpublished data).
3.4. Docking of IPMK requires the PDZ domain and COOH-terminal
tail of Dvl3
Dvl3 is a multivalent scaffold with several well-known domains
(e.g., DIX, PDZ, DEP, and prolyly-rich C-terminal tail) that bind pro-
tein kinases (serine, threonine, and tyrosine-speciﬁc), phosphatases,
and adaptor molecules [16]. We interrogated each of these domains
of Dvl3 to assess if IPMK docking to Dvl3 was dependent on their in-
dividual integrity. Myc-tagged human Dvl3 and a Dvl3 deletion mu-
tant (Fig. 4A) were co-expressed with HA-tagged IPMK in the F9
cells under standard conditions. Cells were lysed and pull-downs of
Myc-tag were performed on the whole-cell lysates (Fig. 4B). The
levels of expression for Myc-tagged Dvl3, or for Myc-Dvl3 mutants
were similar among transfected cells. Likewise, HA-tagged IPMK
expressed in these cells showed at similar levels (Fig. 4B, panels of
total lysates). The pull-downs of Dvl3 (IP: Myc-tag) were probed for
bound IPMK, which was HA-tagged. Results from immunoblotting of
these pull-downs revealed IPMK in the complexes of Myc-tagged
Dvl3. The Dvl3 mutants lacking the DIX (Δ-DIX) or DEP (Δ-DEP) do-
mains actually showed a modest increased content of bound IPMK
than observed for the wild-type Dvl3. In contrast, two of the mutants,
Δ-PDZ and Δ-C-terminal tail Dvl3, failed to dock IPMK (Fig. 4B). Stud-
ies in vitro assaying IPMK binding to puriﬁed Dvl3 domains
Fig. 3. IPMK docking to Dvl3 in response to Wnt3a. F9 clones were transfected with either an empty vector (− or Ctrl) or an expression vector harboring Myc-IPMK. A, Immunoblots of
Myc-IPMK and Dvl3 from Dvl3 pull-downs (top panel) and from total cell lysates (bottom panel) were displayed. B, Clones were treated withWnt3a and cell lysates were collected at in-
dicated time periods. Immunoblots ofMyc-IPMK and Dvl3 fromDvl3 pull-downs (top panel) and from total cell lysates (bottom panel)were prepared. At least 3 independent experiments
were conducted for each experimental design. Immunoblots of actin are shown to demonstrate equal loading of protein samples. C, The intensities of Myc-IPMK in blots obtained from at
least three sets of Dvl3 pull-downs were compared and plotted, setting the value at 0 min of Wnt3a treatment as 1. *pb0.01 versus control (Wnt3a at 0 min) group.
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Dvl3 bind puriﬁed IPMK (data not shown). IPMK docks to Dvl3 direct-
ly, in a manner which is dependent minimally upon the presence of a
PDZ domain and the C-terminal tail of this scaffold protein.Fig. 4.Deletion of either the PDZdomainor theC-terminal “tail”ofDvl3 blocks IPMKdocking.
A, Schematic of Myc-Dvl3 and deletion mutants of Dvl3. B, One Myc-tagged Dvl3 deletion
mutant and HA-tagged IPMK were co-expressed in F9 cells. Immunoblots of Myc and HA
obtained from pull-downs by Myc-antibody (top panel) and total lysates (bottom panel)
are displayed.3.5. N-terminal region of IPMK contributes to membrane targeting
Having identiﬁed the PDZ domain and C-terminal tail of Dvl3 as nec-
essary for IPMK docking, we sought to explore the basis of IPMK trans-
location towards plasma membrane in response to Wnt3a stimulation.
All but the ﬁrst 60 amino acids at the NH2-terminus of mouse IPMK
(mIPMK) are proposed as a kinase domain composed of structures in-
volving with substrate binding and catalytic activity as it was reported
for yeast IPMK [17]. We probed the role of the N-terminus of IPMK by
deletionmutagenesis (Fig. 5A).We treated F9 cells with siRNA targeting
expression of endogenous IPMK. Cellular IPMK content was suppressed
by siRNA treatment (Fig. 5B). The functional status of IPMK mutants
could best be interrogated by “rescue” experiments, in which expres-
sion of a mutant form of human IPMK (hIPMK) were assessed for their
ability to overcome the loss of endogenous IPMK. The siRNA targeting
mouse IPMK reduced, but did not abolish, mIPMK expression in F9
cells. These IPMK-deﬁcient cells were then transfected with expression
vectors harboring hIPMK and assayed for function. The N-terminal
deletion of 77 amino acids of hIPMK (hIPMKΔN) is the human equiva-
lent to N-terminal deletion of 60 amino acids of a mouse homologue
(Fig. 5A). The loss of the N-terminal region of hIPMK resulted in
sharply diminished IPMK content of the cell membrane-enriched
subcellular fraction (Fig. 5C), which is enriched in Na+/K+ ATPase.
Since N-terminal region is proven to be important for IPMK translo-
cation, the second mutant tested the hypothesis that targeting the
hIPMKΔN to the cell membrane artiﬁcially would overcome interrup-
tion in translocation of hIPMKΔN. The approach makes use of introduc-
ing a “CAAX-box” to the C-terminus of a protein. The presence of a
CAAX-box ensures prenylation of the Cys residue, the proteolytic cleav-
age of the three C-terminal amino acids, and methylation of the
isoprenylcysteine residue, which acts as an independent lipid anchor
to the cell membrane [18]. The hIPMKΔNmutantwas engineered to ac-
commodate a C-terminal CAAX-box (hIPMKΔN‐CAAX), ensuring that
the mutant lacking the Dvl3 targeting sequence in the N-terminus
would still localize to the cell membrane. Fluorescence microscopy in-
deed localized the expressed hIPMK-CAAX mutant largely to the cell
membrane (Fig. 5D). Cells expressing hIPMK as well as mutant forms
of hIPMK were assayed for their ability to respond to stimulation by
Wnt3a. The read-out was the activation of the Lef/Tcf-sensitive tran-
scriptional pathway, the hallmark of the canonical Wnt pathway
(Fig 5E). Deﬁciency of endogenous mIPMK sharply attenuated the
ability of Wnt3a to stimulate the activation of Lef/Tcf-sensitive
Fig. 5. N-terminal region of IPMK targets the cell membrane in response to Wnt3a. A, Schematic of IPMK, ΔNhIPMK, and ΔNhIPMK-CAAX. B, F9 clones were treated with either control
siRNA or siRNA targeting IPMK for 24 h. Expression vectors harboring either Myc-ΔNhIPMK or Myc-ΔNhIPMK-CAAX were introduced into siRNA-treated mIPMK-deﬁcient cells, using
an increasing amount of plasmid DNA, as indicated. Immunoblots of Myc, IPMK and actin (as a loading control) are displayed. C, Cell membrane-enriched fractions from cells expressing
either hIPMK or ΔNhIPMKwere collected from cells that were challengedwithWnt3a for the time period indicated. IPMK and ΔNhIPMK content in cell membrane-enriched subcellular
fractions were probed by immunoblotting. The content of each of these proteins in the blots was analyzed by scanning densitometry. The relative amounts of each protein found are
graphed. *pb0.01 versus control (hIPMK, Wnt3a at 0 min) group. D. Indirect immunoﬂuorescence images of F9 cells expressing either Myc-ΔNhIPMK or Myc-ΔNhIPMK-CAAX. DAPI
was used to stain nuclei. E, F9 clones were treated with either a “control” siRNA or siRNA that targets mouse IPMK. Increasing amounts of expression vectors harboring either
Myc-ΔNhIPMK or Myc-ΔNhIPMK-CAAX were employed to transfect the siRNA-treated mIPMK-deﬁcient cells. Twenty four hours after transfection, the cells were stimulated by
Wnt3a for 6 h. Cell lysates were collected and transcriptional reporter Luciferase activity used to measure Lef/Tcf-dependent transcriptional activation. TheWnt3a-stimulated activation
revealed by the reported read-out is displayed. The reporter activity established for the cells treatedwith “control” siRNA-treated group was set as 100%. #pb0.01, versus control (control
siRNA treated) group; *pb0.01 versus knockdown (mIPMK siRNA-treated clones with and without hIPMK or mutant expressed) group.
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fully restored Lef/Tcf-sensitive transcription in response to Wnt3a.
Expression of the hIPMKΔN mutant had only a limited ability to rescue
Lef/Tcf-sensitive transcription. This inability to fully rescue provides a
functional consequence for the earlier noted inability of the N-terminal
deletion mutant to associate with the cell membrane, even when cells
were stimulated with Wnt3a (Fig. 5C). Expression of a hIPMKΔN-CAAX
mutant that is targeted to the cell membrane by the presence of a
C-terminal isoprenylcysteinyl residue not only “rescues” Wnt3a-
stimulated activation of Lef/Tcf-sensitive transcription, but surpasses it
by more than double (Fig. 5E).
4. Discussion
Dishevelleds function as mobile multivalent scaffolds [19]. As
such, Dvls organize the functions of a myriad of proteins that dock
to Dvl3-based signalsomes to function in Wnt signaling, as well as
perhaps other signaling pathways. Proteins docking to Dvl3-based
scaffolds include protein kinases, phosphoprotein phosphatases, Friz-
zled G-protein-coupled receptors, members of the β-catenin destruc-
tion complex, and others [16]. In the current work the repertoire of
docking proteins for Dvl3 is expanded to include IPMK, a protein ki-
nase implicated in the inositol metabolism. The observations rein-
force the role of IPMK in Wnt signaling [10]. Most notable is that
suppression of IPMK expression with siRNA attenuates the ability of
Wnt to activate canonical signaling.
An association of IPMK with Dvl3 is shown at several levels. The
docking of IPMK to Dvl3 was established by pull-downs of Dvl3 that re-
vealed the presence of IPMK. Further, the amount of IPMK associated
with Dvl3-based supermolecular complexes increased in response to
treating the cells with Wnt3a. Wnt3a stimulates increased associationof IPMK with the cell membrane. Based upon the ability of Wnt3a to
provoke translocation of Dvl3 to the cell membrane [20], we speculated
that in response toWnt3a, IPMKdocking to Dvl3 andmigration of IPMK
to the cell membrane might be linked. As metabolism of inositol-
containing lipids and their derivatives of water-soluble inositides
occur in the proximity of the cell membrane, migration of IPMK via
docking to Dvl3-based scaffold in response to Wnt3a might provide a
mechanism for integrating the water-soluble inositides and down-
stream Wnt signaling. Docking studies in vitro also demonstrate that
IPMK binds to Dvl3 (data not shown). The binding is direct and requires
PDZ and C-terminal domains of Dvl3 for IPMK docking. This observation
does not preclude, however, the possibility that IPMKmight dock to ad-
ditional proteins other than Dvls during Wnt-stimulated signaling.
More insightful were results of studies of twomutant forms of IPMK
that focused on the leading N-terminal region of the kinase. The ﬁrst
mutant lacked the N-terminal 1–77 amino acid region of the native
IPMK, hIPMKΔN. The region is unstructured and not necessary for ki-
nase function. Expression of the hIPMKΔN mutant allowed us to
probe if the N-terminus of the IPMK was involved in cell membrane
targeting. In cells made deﬁcient in endogenous IPMK, expression of
the hIPMKΔN mutant failed to rescue Wnt signaling. The reduction in
function likely reﬂects the inability of the IPMKΔN mutant to associate
with the cell membrane in vivo, in response to Wnt3a. We tested
whether the loss-of-function observed for the ΔN mutant of IPMK
could be reversed if the protein could be directed to the cell membrane
by an independent mean. To artiﬁcially target hIPMKΔN to the cell
membrane, a CAAX-box was added to the C-terminus. The resultant
hIPMKΔN mutant lacking the N-terminal (1–77) region localized to
the cell membrane. More importantly, hIPMKΔN‐CAAX expression
was able to rescue the loss-of-function induced by the ΔN mutation in
the context of IPMK-deﬁcient cells. Not only did the hIPMKΔN-CAAX
2395Y. Wang, H. Wang / Cellular Signalling 24 (2012) 2389–2395rescue the function, it dramatically potentiated the effects of Wnt3a on
Lef/Tcf-dependent transcriptional activation.
IPMK catalyzed IP5 formation and is an important signalingmolecule
in Wnt canonical signaling [10]. IPMK activity and translocation to the
cell membrane is necessary for Wnt activation of the canonical signal-
ing. Like other key proteins in these signaling pathways, IPMK docks
to the Dvl3-based scaffold. IPMK can dock Dvl3 directly, although this
does not preclude IPMK docking to other proteins in the very large
Dvl3-based signalsome. The unique need for a mobile scaffold like
Dvl3 to organize docking molecules at the cell membrane is reinforced
herein by studies of IPMK. The dynamic character of Dvl-based sig-
nalsome formation and translocation to the cell membrane is well docu-
mented, established biochemically by steric-exclusion chromatography
on large-bore matrices, optically, by ﬂuorescence correlation spectrosco-
py in live cells challenged with Wnt3a, and by simple ﬂuorescence mi-
croscopy that ﬁrst revealed very large Dvl-based punctae behaving as
we now know signalsome do [11,12,21]. Each of these distinctly different
methodologies of interrogationdiscernDvl3-based complexes to be large,
dynamic in character, functioning and changing locale in response toWnt
signaling. IPMK plays a critical functional role and the current work now
places IPMK within the context of Dvl3-based signalsome that translo-
cates to the cell membrane early in the activation of the canonical path-
way by Wnt.
5. Conclusion
IMPK mediates Wnt3a activated canonical signaling pathway.
Translocation of IPMK to plasma membrane via docking Dvl3 is im-
portant for IPMK to access substrates and generate IP5, activating
down-stream signaling.
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